These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29602288)

  • 1. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy.
    Shoeibi A; Olfati N; Litvan I
    Expert Opin Investig Drugs; 2018 Apr; 27(4):349-361. PubMed ID: 29602288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational therapeutics for the treatment of progressive supranuclear palsy.
    Coughlin DG; Litvan I
    Expert Opin Investig Drugs; 2022 Aug; 31(8):813-823. PubMed ID: 35695010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis of progressive supranuclear palsy: current opinions and challenges.
    Ali F; Josephs K
    Expert Rev Neurother; 2018 Jul; 18(7):603-616. PubMed ID: 29902389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for progressive supranuclear palsy.
    Giagkou N; Stamelou M
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):83-92. PubMed ID: 31007097
    [No Abstract]   [Full Text] [Related]  

  • 5. A Review of Treatment Options for Progressive Supranuclear Palsy.
    Stamelou M; Höglinger G
    CNS Drugs; 2016 Jul; 30(7):629-36. PubMed ID: 27222018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
    Lozupone M; Dibello V; Daniele A; Solfrizzi V; Resta E; Panza F
    Expert Opin Pharmacother; 2024 Apr; 25(5):571-584. PubMed ID: 38653731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.
    Boxer AL; Yu JT; Golbe LI; Litvan I; Lang AE; Höglinger GU
    Lancet Neurol; 2017 Jul; 16(7):552-563. PubMed ID: 28653647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.
    Anand K; Sabbagh M
    Expert Opin Investig Drugs; 2015; 24(10):1355-60. PubMed ID: 26289787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive Supranuclear Palsy: an Update.
    Armstrong MJ
    Curr Neurol Neurosci Rep; 2018 Feb; 18(3):12. PubMed ID: 29455271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.
    Liscic RM; Srulijes K; Gröger A; Maetzler W; Berg D
    Acta Neurol Scand; 2013 May; 127(5):362-70. PubMed ID: 23406296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions in progressive supranuclear palsy.
    Koros C; Stamelou M
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S93-5. PubMed ID: 26459661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased basal ganglia binding of
    Smith R; Schain M; Nilsson C; Strandberg O; Olsson T; Hägerström D; Jögi J; Borroni E; Schöll M; Honer M; Hansson O
    Mov Disord; 2017 Jan; 32(1):108-114. PubMed ID: 27709757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive supranuclear palsy: a systematic review.
    Rampello L; Buttà V; Raffaele R; Vecchio I; Battaglia G; Cormaci G; Alvano A
    Neurobiol Dis; 2005 Nov; 20(2):179-86. PubMed ID: 16242626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive supranuclear palsy--parkinsonian disorder with tau pathology.
    Kowalska A; Jamrozik Z; Kwieciński H
    Folia Neuropathol; 2004; 42(2):119-23. PubMed ID: 15266787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progressive supranuclear palsy; an unusual form of parkinsonism].
    Donker Kaat L; Boon AJ; Heutink P; van Swieten JC
    Ned Tijdschr Geneeskd; 2004 Mar; 148(11):519-23. PubMed ID: 15054950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.
    Coakeley S; Cho SS; Koshimori Y; Rusjan P; Harris M; Ghadery C; Kim J; Lang AE; Wilson A; Houle S; Strafella AP
    J Cereb Blood Flow Metab; 2017 Sep; 37(9):3150-3160. PubMed ID: 28155586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases?
    Sha S; Hou C; Viskontas IV; Miller BL
    Nat Clin Pract Neurol; 2006 Dec; 2(12):658-65. PubMed ID: 17117169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome.
    Tsuboi Y; Josephs KA; Boeve BF; Litvan I; Caselli RJ; Caviness JN; Uitti RJ; Bott AD; Dickson DW
    Mov Disord; 2005 Aug; 20(8):982-8. PubMed ID: 15834857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.
    Poewe W; Mahlknecht P; Krismer F
    Mov Disord; 2015 Sep; 30(11):1528-38. PubMed ID: 26227071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers.
    Jabbari E; Zetterberg H; Morris HR
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):883-888. PubMed ID: 28600442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.